161 related articles for article (PubMed ID: 30911639)
21. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Lepistö A
Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
[TBL] [Abstract][Full Text] [Related]
22. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
23. Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
Bartoška P; Antoš F; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
Rozhl Chir; 2020; 99(4):159-166. PubMed ID: 32545978
[TBL] [Abstract][Full Text] [Related]
24. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
[TBL] [Abstract][Full Text] [Related]
25. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience.
Santullo F; Pacelli F; Abatini C; Attalla El Halabieh M; Fortunato G; Lodoli C; Giovinazzo F; Rotolo S; Di Giorgio A
Front Surg; 2021; 8():715119. PubMed ID: 34513915
[No Abstract] [Full Text] [Related]
26. Pseudomyxoma peritonei: a review of 62 cases.
van Ruth S; Acherman YI; van de Vijver MJ; Hart AA; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2003 Oct; 29(8):682-8. PubMed ID: 14511618
[TBL] [Abstract][Full Text] [Related]
27. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
[TBL] [Abstract][Full Text] [Related]
28. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Sugarbaker PH
Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
[TBL] [Abstract][Full Text] [Related]
30. Novel Perspectives in Pseudomyxoma Peritonei Treatment.
Sommariva A; Tonello M; Rigotto G; Lazzari N; Pilati P; Calabrò ML
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885075
[TBL] [Abstract][Full Text] [Related]
31. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
32. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.
Cioppa T; Vaira M; Bing C; D'Amico S; Bruscino A; De Simone M
World J Gastroenterol; 2008 Nov; 14(44):6817-23. PubMed ID: 19058307
[TBL] [Abstract][Full Text] [Related]
33. Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines.
Lin YL; Xu DZ; Li XB; Yan FC; Xu HB; Peng Z; Li Y
Orphanet J Rare Dis; 2021 Feb; 16(1):85. PubMed ID: 33581733
[TBL] [Abstract][Full Text] [Related]
34. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
35. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
36. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
37. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Invest New Drugs; 2012 Oct; 30(5):2080-6. PubMed ID: 22359216
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of the presence of epithelial cell clusters in the ascites of patients with pseudomyxoma peritonei.
Ishida M; Mizumoto A; Yonemura Y; Kashu I; Takemura S; Tsuta K
Diagn Cytopathol; 2019 Oct; 47(10):1024-1027. PubMed ID: 31218847
[TBL] [Abstract][Full Text] [Related]
39. Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix.
Honoré C; Caruso F; Dartigues P; Benhaim L; Chirica M; Goéré D; Elias D
Anticancer Res; 2015 Sep; 35(9):4943-7. PubMed ID: 26254392
[TBL] [Abstract][Full Text] [Related]
40. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
